Brief: Apollomics Announces Results For Phase 3 Bridging Trial Of Uproleselan In China

Apollomics

20/12/2024 14:20

Dec 20 (Reuters) - Apollomics Inc  APLM.O :
    * APOLLOMICS ANNOUNCES TOP-LINE RESULTS FOR PHASE 3 BRIDGING
TRIAL
OF UPROLESELAN IN CHINA IN PATIENTS WITH RELAPSED OR REFRACTORY
ACUTE MYELOID LEUKEMIA
    * TRIAL DID NOT DEMONSTRATE FAVORABLE BENEFIT FOR
UPROLESELAN
    * SERIOUS ADVERSE EVENTS 43% IN UPROLESELAN ARM VERSUS 39%
IN
CONTROL

Source text:  ID:nGNX7xNhb 
Further company coverage:  APLM.O 

 ((Reuters.Briefs@thomsonreuters.com;))